Technology and innovation play a pivotal role towards enhancing healthcare systems, increasing access to healthcare services, and reducing costs of therapies and consultations
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
The company has also been named among global sustainability leaders for the 7th year in a row in the Dow Jones Sustainability Index in the Emerging Markets category
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
A pharma industry veteran with over three decades of experience in domestic as well as international markets
He is a Chartered Accountant with more than 19 years of extensive experience
During the quarter, foreign exchange fluctuations had an impact of Rs. 4.56 crore Q3 FY23 Profit After Tax after considering exchange rate fluctuations stood at Rs. 8.2 crore
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
Subscribe To Our Newsletter & Stay Updated
